Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/14—Blood; Artificial blood
  • A61K35/16—Blood plasma; Blood serum
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/14—Blood; Artificial blood
  • A61K35/19—Platelets; Megacaryocytes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/18—Growth factors; Growth regulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0043—Nose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

• the invention relates to a composition obtained from at least one blood compound with growth factors, intended for intranasal treatment of a neurodegenerative disease or other applicable pathology.
• the invention also relates to the method of manufacturing said composition or a therapeutic substance obtained from said composition, and to the method of intranasally treating said neurodegenerative disease or other pathology applicable by means of the therapeutic composition or substance.
• compositions from blood compounds containing growth factors obtained from the blood of a patient
• These compositions have been shown to offer very important biological properties, especially related to the triggering and favoring of tissue regeneration, the reduction of pain in certain types of ailments and diseases, and other multiple utilities.
• some widespread uses of compositions obtained from blood compounds rich in growth factors have been the regeneration of alveolar bone in oral cavities during implantological and other procedures, the regeneration of tissues of the musculoskeletal system (muscles, joints, tendons, etc.) and others.
• patent application WO0044314A1 and patent application WO2010130851 A2 are known, both in favor of the applicant himself of the present invention.
• These patents refer to procedures for preparing an autologous blood plasma gel, rich in growth factors, from the patient's own blood. Both procedures share common steps such as centrifugation of the patient's blood, separation of platelet rich plasma and the addition of calcium chloride to platelet rich plasma to produce plasma activation (the release of growth factors by platelets contained in the plasma) and to produce coagulation thereof until the plasma acquires a gel-like consistency.
• the present invention aims to broaden the therapeutic horizons of application of the plasma gel rich in growth factors, of the plasma supernatant rich in growth factors or, in general, of any composition obtained from a blood compound containing factors of increase.
• the object of the invention is the treatment of neurodegenerative diseases or other applicable pathologies by means of a composition obtained from at least one blood compound with growth factors, or by a therapeutic substance obtained from said composition.
• the means of application of the composition or of the therapeutic substance, according to the invention, to deliver it to the central nervous system effectively from the point of view of the treatment and at the same time safely for the patient, is intranasal application.
• the intranasal route is an access route to the non-invasive central nervous system, which allows a remarkable ease of application of the therapeutic composition or substance and therefore of carrying out the treatment, since unlike the invasive routes it does not require continuous injections or other traumatic means of application for the patient or produce side effects on the patient.
• the intranasal route is a very relevant non-invasive route from the point of view of access to the central nervous system, since such access is impossible by other non-invasive routes due to the existence of different physiological barriers, between which highlights the blood brain barrier.
• FIG. 1 shows results of studies in which the formation of beta-amyloid plaques has been measured at three and six months in APP / PS1 transgenic mice treated by a plasma rich in growth factors applied intranasally.
• FIG. 4 shows results of studies in which neurogenesis has been measured at six months in APP / PS1 transgenic mice treated by a growth factor-rich plasma applied intranasally.
• the central nervous system responsible for receiving and processing the sensations collected by the different senses and transmitting the response orders accurately to the different effectors .
• the cells that form the central nervous system are arranged in such a way that they give rise to two very characteristic formations: the gray substance, constituted by the neuronal bodies, and the white substance, formed mainly by the nerve extensions (dendrites and axons) , whose function is to conduct information.
• Neurodegenerative disease is known as the type of diseases that groups a genre of cognitive disorders, such as Alzheimer's, Parkinson's, Huntington's, Creutzfeldt-Jakob's disease or multiple sclerosis among others. These cognitive disorders are caused by an increase in cell death processes, which greatly reduces the number of neurons and generates changes in behavior and a progressive global degeneration that causes the patient's death. In addition, in many of These pathologies are alterations of blood flow at the brain level that produce more or less important lesions depending on the location and size of the affected area and the time during which the patient remains without proper treatment.
• trophic agents substances that influence axon growth and synapse formation, and that favor the survival of the cells of the central nervous system
• antiapoptotics substances that reduce cell death
• Neovascularization inducers substances that promote the formation of blood vessels
• the administration of substances at the level of the central nervous system entails important galenic and technological difficulties due to the anatomical peculiarities of this area and the difficult access of substances at this level.
• the central nervous system which is made up of the brain and spinal cord, is strongly isolated from the rest of the organism and from the external environment by three membranes: dura mater (outer membrane), arachnoid (intermediate membrane), pia mater (inner membrane) generically called meninges.
• the brain and spinal cord are protected by bone envelopes, which are the skull and spine respectively.
• cerebrospinal fluid a colorless and transparent fluid, which is called cerebrospinal fluid.
• the functions of the cerebrospinal fluid are very varied: it serves as a means of exchanging certain substances, as a waste disposal system, to maintain the proper ionic balance and as a mechanical buffer system.
• the invention proposes, in order to overcome the needs current treatment of diseases of the central nervous system in a viable way, the treatment of said diseases (or even other applicable pathologies) by a composition obtained from at least one blood compound with growth factors (which comprises therapeutic agents that are described below), or by a therapeutic substance obtained from a composition obtained in turn from at least one blood compound with growth factors.
• the means of application of the composition or of the therapeutic substance, according to the invention, to deliver it to the central nervous system effectively from the point of view of the treatment and at the same time safely for the patient, is intranasal application.
• the intranasal route is an access route to the non-invasive central nervous system, which allows a remarkable ease of application of the composition or of the therapeutic substance and of carrying out the treatment, since unlike the invasive routes it does not require continuous injections or other traumatic means of application for the patient or produce side effects on the patient. It should also be noted that the intranasal route is a very relevant non-invasive route from the point of view of access to the central nervous system, since such access is impossible by other non-invasive routes due to the existence of different physiological barriers. In addition, intranasal administration is simple, safe and easy to use, which will allow the patient to be given medication without the need for help from other people.
• the application of the blood compound with intranasal growth factors allows the arrival of the blood compound and its therapeutic agents to the central nervous system and the achievement of its biological effects in the manner explained below.
• the olfactory and trigeminal nerves which innervate the nasal cavity, provide a direct connection of the nasal cavity with the central nervous system.
• the trigeminal does not provide branches to the olfactory region but innervates the respiratory epithelium and the vestibule of the nasal cavity;
• it establishes a connection with the central nervous system, especially with the caudal region of the brain, the brain stem and the spinal cord, and transmits the sensory information from the nasal cavity to these regions.
• these conditions give the nasal mucosa some very particular anatomical and physiological attributes, which facilitate the introduction of therapeutic means into the body that can reach the central nervous system after nasal instillation, and thus circumvent the blood-brain barrier.
• intracellular, extracellular and pericular transport mechanisms can be produced.
• the intracellular route of a substance to the central nervous system is done through the uptake of said substance by the dendrites of olfactory neurons, by pinocytosis or by simple diffusion, and subsequent transfer by the olfactory nerve.
• the mechanism of extracellular or paracellular transport facilitates the passage of the substance between the cells of the nasal epithelium and its rapid entry into the perineural channels (created by the olfactory enveloping cells that surround the branches of the olfactory nerve), which allows the substance reach the cerebrospinal fluid and the olfactory bulb.
• the substance can be mixed with the interstitial fluid present in the brain, which facilitates its distribution throughout this organ; In addition, the substance can enter the pervascular spaces existing in the nasal mucosa and brain tissue to be distributed rapidly throughout the central nervous system.
• blood compound with growth factors is meant a plasma gel containing growth factors, a plasma supernatant containing growth factors or, in general, any autologous blood compound (donor and recipient is the same person) or heterologous ( Donor and recipient are different people) prepared according to any applicable preparation method. Growth factors may or may not be released.
• the supernatant, gel or other blood compound may have been recently prepared, or it may have been previously prepared and stored (for example by the technique of heat treatment, lyophilization and subsequent re-suspension proposed by patent application ES2369945A1 in favor of own applicant).
• composition any composition obtained from at least one blood compound as described, the composition may or may not contain blood cell components (platelets, erythrocytes and white blood cells).
• therapeutic substance is meant the composition itself or a substance obtained from said composition for therapeutic purposes.
• composition obtained from at least one blood compound with growth factors is object of the invention, for use as an intranasal application medicament for the treatment of a neurodegenerative disease.
• the composition be a supernatant and that the blood compound with growth factors be a blood plasma.
• a supernatant is the subject of the invention, for use as a therapeutic substance for intranasal application for the treatment of a neurodegenerative disease.
• the liquid nature of the supernatant, its fluidity and osmotic properties make it an ideal preparation for nasal administration.
• the composition is a gel and the blood compound with growth factors is a blood plasma.
• such gel is the subject of the invention, for use as a therapeutic substance for intranasal application for the treatment of a neurodegenerative disease
• the use of a gel-like composition allows the transfer of growth factors for several weeks, which in turn allows reducing the number of times the patient should administer the composition.
• the object of the invention is also a method of manufacturing a therapeutic substance for the treatment of a neurodegenerative disease intranasally, characterized in that said method comprises the use of at least one composition obtained in turn from at least one blood compound with growth factors.
• the composition be a supernatant and that the blood compound with growth factors be a blood plasma.
• a method of manufacturing a therapeutic substance for the treatment of a neurodegenerative disease intranasally is subject, based on whether the therapeutic substance is directly said supernatant or treatments are applied on said supernatant to provide it with a consistency or presentation especially indicated for intranasal application.
• the composition is a gel and the blood compound with growth factors is a blood plasma.
• a method of manufacturing a therapeutic substance intended for the treatment of a neurodegenerative disease intranasally is subject, based on whether the therapeutic substance is directly said gel or treatments are applied on said gel to provide it with a consistency or presentation especially indicated for intranasal application.
• the object of the invention is also a method of treatment of a neurodegenerative disease, wherein said method of treatment comprises the intranasal application of a therapeutic substance obtained from a composition obtained in turn from at least one blood compound with growth factors. .
• the composition be a supernatant and that the blood compound with growth factors be a blood plasma.
• a method of treating a neurodegenerative disease is based on the invention, based on the intranasal application of a therapeutic substance that may be the supernatant itself or a product in turn derived from the supernatant.
• the composition is a gel and that the blood compound with growth factors is a blood plasma.
• a method of treating a neurodegenerative disease is based on the invention, based on the intranasal application of a therapeutic substance that can be the gel itself or a product derived from the gel.
• Figure 1 shows results of studies in which the formation of beta-amyloid plaques has been measured at three and six months in APP / PS1 transgenic mice. Plaque density has been specifically measured in animals treated intranasally with a Growth Factor-Rich Plasma (PRGF), compared to a control group consisting of untreated diseased animals. PRGF has been obtained for these experiments by the preparation method described in US6569204.
• Beta-amyloid ( ⁇ ) is a peptide of 36 to 43 amino acids that is synthesized from the amyloid precursor protein. Although it is generally known for its relationship with Alzheimer's disease, it is not yet known whether it is the cause or effect of the disease.
• Beta-amyloid is the main component of senile plaques (deposits found in the brains of patients with the disease of Alzheimer's)
• An increase in total levels of ⁇ or an increase in the concentration of both ⁇ 40 and ⁇ 42 is completely related to the pathogenesis of Alzheimer's disease.
• the data in Figure 1 correspond to both the cortex region (Cx) and the hippocampus (Hip), also showing the CA1 area of the hippocampus and the dentate gyrus (DG). The results clearly show how animals that received PRGF intranasally present significantly lower levels of plaques, regardless of location and follow-up time.
• Figure 2 shows results of studies in which the amount of beta-amyloid in its AB40 and AB42 form has been measured at three and six months in APP / PS1 transgenic mice treated with PRGF, compared to a control group formed for sick untreated animals.
• the data correspond to both the cortex region (Cx) and the hippocampus (Hip).
• the results clearly show how animals that received PRGF intranasally present significantly lower levels of both types of beta-amyloid, partly responsible for neuronal damage, regardless of location and follow-up time.
• Figure 3 shows results of studies in which the degree of astrogliosis or abnormal astrocyte growth has been measured due to the destruction of nearby neurons in transgenic APP / PS1 mice treated with PRGF, compared to a control group consisting of sick animals untreated
• Astrocytes are the main and most numerous glial cells (cells of the nervous system that support neurons and are actively involved in the brain's processing of information in the body).
• the presence of astrogliosis is an indication of the toxicity present in the brain.
• beta-amyloid plaques increases the levels of reactive astrocytes or astrogliosis.
• the data correspond to both the cortex region (Cx) and the hippocampus (hip) and the dentate gyrus (DG).
• FIG. 4 shows results of studies in which neurogenesis (differentiation of new neurons from precursor cells) has been measured at six months in APP / PS1 transgenic mice treated with PRGF, compared to a control group consisting of untreated sick animals. The data correspond to the hippocampus region (Hip). The results clearly show how animals that received PRGF intratransally presented significantly higher neurogenesis. Using different types of stains (corresponding to the first, second and third pair of comparative photographs) the presence of a greater number of new cells can be observed in the histologies belonging to the group treated with PRGF.
• Figure 5 shows the results of two behavioral tests that assess short and medium term memory and other symptoms associated with Alzheimer's disease such as apathy.
• the tests have been carried out on three groups of APP / PS1 transgenic mice: a group of healthy animals, a control group consisting of sick animals (with Alzheimer's disease) not treated and a group of animals with the same disease but treated with PRGF by intranasal route.
• the data reflects that transgenic APP / PS1 mice that received PRGF intratransally show recovery values in behavioral tests, reflecting a significant improvement over untreated diseased mice.
• the animals were placed in a T-maze labyrinth where one of the lateral arms of the labyrinth had been initially closed and the animals were allowed to complete the other arm. Subsequently, the animals were introduced again and analyzed in time they needed to go to the arm they knew from the previous experiment.
• the animals of Control group did not remember well what was done and showed apathy and fear, which took them longer to complete the experiment. In contrast, sick animals that received intranasal treatment finished the experiment in a significantly shorter time than the control group animals, that is, untreated patients.
• the second test or study of object recognition was based on the exploration by the animal of a perfectly identified central area within a square-shaped space.
• a sick animal shows difficulties in exploring new areas, especially when those areas are not close to the walls, which causes them to fear the unknown.
• the time that the animals spent in the central delimited area was quantified and compared with the total recognition time (the graph shows the ratio of the first time and the second time, so that a higher ratio indicates a higher cognitive situation ).
• the behaviors of identical three groups of animals were measured than in the previous trial. As can be seen, the animals treated with PRGF suffered a significant improvement in their behavior both at three and six months with respect to the untreated sick animals (control group).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Hematology (AREA)
• Biomedical Technology (AREA)
• Immunology (AREA)
• Zoology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Cell Biology (AREA)
• Virology (AREA)
• Developmental Biology & Embryology (AREA)
• Biotechnology (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Gastroenterology & Hepatology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Otolaryngology (AREA)
• Psychiatry (AREA)
• Hospice & Palliative Care (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicinal Preparation (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (1)

Family

ID=49111229

Family Applications (1)

Country Status (17)

Families Citing this family (1)

Citations (5)

Family Cites Families (8)

• 2012
  • 2012-08-09 ES ES201200810A patent/ES2442242B1/es not_active Expired - Fee Related
• 2013
  • 2013-07-19 BR BR112015002760A patent/BR112015002760A2/pt not_active Application Discontinuation
  • 2013-07-19 CA CA2881075A patent/CA2881075A1/en not_active Abandoned
  • 2013-07-19 CN CN201380041280.4A patent/CN104519961A/zh active Pending
  • 2013-07-19 RU RU2015104076A patent/RU2696497C2/ru active
  • 2013-07-19 TW TW102125858A patent/TWI649084B/zh not_active IP Right Cessation
  • 2013-07-19 WO PCT/ES2013/000176 patent/WO2014023860A1/es not_active Ceased
  • 2013-07-19 JP JP2015525915A patent/JP6339568B2/ja not_active Expired - Fee Related
  • 2013-07-19 MX MX2015001677A patent/MX357828B/es active IP Right Grant
  • 2013-07-19 ES ES13756518.0T patent/ES2662385T3/es active Active
  • 2013-07-19 KR KR1020157001551A patent/KR102149162B1/ko not_active Expired - Fee Related
  • 2013-07-19 EP EP13756518.0A patent/EP2883569B1/en not_active Not-in-force
  • 2013-07-19 PE PE2015000116A patent/PE20150616A1/es not_active Application Discontinuation
  • 2013-08-08 US US13/962,340 patent/US20140044795A1/en not_active Abandoned
  • 2013-08-08 AR ARP130102835A patent/AR092086A1/es unknown
• 2014
  • 2014-12-23 CL CL2014003510A patent/CL2014003510A1/es unknown
  • 2014-12-31 IN IN2675MUN2014 patent/IN2014MN02675A/en unknown
• 2015
  • 2015-01-20 CO CO15010369A patent/CO7170177A2/es unknown
• 2016
  • 2016-03-08 US US15/063,969 patent/US20160184360A1/en not_active Abandoned

Patent Citations (7)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events